Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Radiolabeled Androxal in Healthy Males
NCT02274181Phase 1Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Dec 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enclomiphene in secondary hypogonadism (HH), sponsored by Repros Therapeutics Inc. Primary endpoint: Percentage of Androxal excreted via the urine, feces and blood at 8 Days. Started Dec 2014; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT02274181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274181.